# Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

> **NCT02420717** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Recurrent B Acute Lymphoblastic Leukemia
- Recurrent Ph-Like Acute Lymphoblastic Leukemia
- Refractory B Acute Lymphoblastic Leukemia
- Refractory Ph-Like Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dasatinib
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Leucovorin
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate
- **DRUG:** Prednisone
- **BIOLOGICAL:** Rituximab
- **DRUG:** Ruxolitinib Phosphate
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT02420717
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-15
- **Primary completion:** 2021-01-20
- **Final completion:** 2021-01-20
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Study was closed early due to low accrual and lack of response.
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02420717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02420717, "Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02420717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*